These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31463990)

  • 1. Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
    Im JJ; Jeong H; Chung YA; Park JS; Heo Y; Oh JK; Song IU
    J Neuroimaging; 2019 Nov; 29(6):707-711. PubMed ID: 31463990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible neuroprotective effects of rasagiline in Alzheimer's disease: a SPECT study.
    Song IU; Im JJ; Jeong H; Na SH; Chung YA
    Acta Radiol; 2021 Jun; 62(6):784-790. PubMed ID: 32646230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E; Stern MB
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
    Zhang L; Zhang Z; Chen Y; Qin X; Zhou H; Zhang C; Sun H; Tang R; Zheng J; Yi L; Deng L; Li J
    Int J Neuropsychopharmacol; 2013 Aug; 16(7):1529-37. PubMed ID: 23551956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
    Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
    Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    Hoy SM; Keating GM
    Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic Parkinson's disease: a meta-analysis of randomised controlled trials.
    Cai JP; Chen WJ; Lin Y; Cai B; Wang N
    Eur Neurol; 2015; 73(1-2):5-12. PubMed ID: 25358603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
    Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Nakaya R; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):289-297. PubMed ID: 30635744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasagiline: a guide to its use in Parkinson's disease.
    Keating GM; Lyseng-Williamson KA; Hoy SM
    CNS Drugs; 2012 Sep; 26(9):781-5. PubMed ID: 22834567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of rasagiline in early Parkinson's disease.
    Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ
    Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review.
    Jiang DQ; Wang HK; Wang Y; Li MX; Jiang LL; Wang Y
    Neurol Sci; 2020 Jan; 41(1):101-109. PubMed ID: 31446579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.